Needham analyst Gil Blum lowered the firm’s price target on Crispr Therapeutics to $82 from $122 but keeps a Buy rating on the shares after its Q4 results. The analyst is updating the firm’s valuation methodology, rolling out the valuation year to 2023-end, assigning $2B to the company pipeline, and also assuming the following probabilities of success: 80% CTX001, 50% CTX110, 15% CTX121, 25% CTX130, and 10% CTX131.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CRSP:
- Crispr Therapeutics price target lowered to $123 from $153 at Chardan
- Crispr Therapeutics price target lowered to $65 from $78 at Credit Suisse
- CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
- Crispr Therapeutics options imply 4.4% move in share price post-earnings
- Crispr Therapeutics options imply 4.9% move in share price post-earnings
